Elisa R Port, MD
- ASSOCIATE PROFESSOR | Surgery
Specialties:Breast Cancer - Surgery, Surgical Oncology, Surgery
I am a surgeon who specializes in the care and treatment of patients with breast cancer, and those at increased risk for breast cancer. I have extensive experience with sentinel lymph node biopsy, nipple sparing mastectomy, and the newest techniques in breast cancer surgery for both invasive breast cancer and DCIS.
I am the author of a variety of publications on the role of sentinel lymph node biopsy in breast cancer, the role of MRI in patients at high risk for breast cancer, and I have received a Komen Foundation Grant investigating the role of PET scanning in breast cancer. I recently completed an NCI funded clinical trial investigating the effects of the COX2 inhibitor, Celebrex, on breast cancer tissue.
I am a member of many professional organizations including the Society of Surgical Oncology, the American Society of Breast Diseases, the American Society of Breast Surgeons, and the American College of Surgeons Oncology Group.
In the News
Dr. Port and Dr. Raptis discuss breast cancer in The Daily News feature The Daily Check Up.
American Board of Surgery
BA, Dartmouth College
MD, Mount Sinai School of Medicine
Residency, General Surgery, Cedars-Sinai Medical Center
Residency, General Surgery, Long Island Jewish Medical Center
Fellowship, Research Fellow, Memorial Sloan Kettering Cancer Center
Honors in Surgery
Third Honor Group
MRI in women at increased risk for breast cancer
NCI Sponsored Trial
Investigating COX-2 inhibition and aromatase activity in breast cancer
Applications of sentinel lymph node biopsy for breast cancer
Susan G. Komen Foundation Research Grant
Study of the role of Positron Emission Tomography (PET) scanning in the pre-operative management of patients with breast cancer
- Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers
The purpose of this study is to evaluate whether breast conservation surgery, also known as lumpectomy, can be used to remove the 2 or 3 tumors in your br...
Port ER, Patil S, Stempel M, Morrow M, Cody HS. The Number of Nodes Removed in Sentinel Node-Negative Breast Cancer Patients is Significantly Related to Patient Age and Tumor Size: A New Source of Bias in Morbidity Assessment? . Cancer 2010 FEB;.
Chung A, Schoder H, Sampson M, Morrow M, Port ER. Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose-Positron Emission Tomography. . Ann Surg Oncol 2010 FEB;.
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Flowers C, Troyan S, Garber J, Olopade O, Hylton N, Port ER, Campbell MC, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. . Breast Can Res Treat 2010; 119(1): 137-144.
Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. . Ann Surg Oncol 2009 JUL; 16(7): 1952-1958.